• BioLineRx Ltd., of Jerusalem, said it received approval from Indian regulators to start the Phase II/III CLARITY trial of BL-1020, an oral GABA-enhanced antipsychotic for treating schizophrenia. Overall, the study is expected to be conducted at about 18 sites in India, 14 sites in Romania and four sites in Israel.